PATENT CLAIM ANALYSIS

Application Number: 16270317
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-05
Patent Classification: ["424", "130100"]

Abstract:
The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

Claim (Index 73):
The immunoconjugate of  claim 63 , wherein the antibody is an antibody fragment.

Metadata:
- Claim Count in Document: 86.0
- Percentile: 99.0
- Lexical Diversity: 1.42105
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15938961', '15325364', '15533049', '13704388', '14854613']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8276160584707063
- 35 USC 102 Novelty (BERT): 0.5989822980002916
- Combined Prediction Score: 0.8047526824236648
- Mean Citation Score: 500.004312
- Max Citation Score: 681.9164400000002
- Similarity Product: 424.970853342805

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test